Roche Diagnostics has developed a groundbreaking Elecsys NfL test, offering a crucial tool for individuals managing multiple sclerosis.
The Elecsys NfL test serves as a valuable aid in identifying disease activity among adults aged 18-55 with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS). Its insights are pivotal for effectively managing the disease.
The Elecsys NfL presents a minimally invasive testing alternative tailored to swiftly deliver answers to patients and caregivers. Its potential extends beyond multiple sclerosis, offering valuable patient insights for other neurological conditions like Alzheimer’s and Huntington’s diseases.
Elecsys NfL test measures NfL protein, which is present in neurons and is an indicator of neuroaxonal damage. Abnormally elevated levels of NfL in cerebrospinal fluid can be used to detect neurological damage.
NfL, an exclusive protein in neurons, is highly sensitive to neuroaxonal damage. Its normal release at low levels from axons increases with age and damage. Elevated NfL appears in cerebrospinal fluid and blood across various acute and chronic neurological disorders.
While initially focused on multiple sclerosis, increased NfL levels are observed in traumatic brain injury, amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Huntington's, and more neurodegenerative diseases, as well as indications beyond neurology.
Roche’s Elecsys NfL test, a critical tool for individuals grappling with multiple sclerosis, has been granted the FDA breakthrough device designation.
